Jackson Square Partners LLC Reduces Stock Position in Eli Lilly and Company $LLY

Jackson Square Partners LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 12.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,767 shares of the company’s stock after selling 560 shares during the period. Jackson Square Partners LLC’s holdings in Eli Lilly and Company were worth $2,936,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter worth about $27,000. Blume Capital Management Inc. increased its holdings in Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after acquiring an additional 14 shares during the period. IMG Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $35,000. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company in the 1st quarter valued at $40,000. Finally, TD Capital Management LLC grew its position in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gabrielle Sulzberger bought 117 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders acquired 4,314 shares of company stock valued at $2,766,929. Insiders own 0.14% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on LLY shares. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Guggenheim reissued a “buy” rating and issued a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Morgan Stanley lowered their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research report on Friday, October 3rd. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Finally, UBS Group upped their target price on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $960.88.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $923.35 on Friday. The company has a market cap of $872.92 billion, a price-to-earnings ratio of 60.35, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $955.46. The company has a 50-day moving average price of $799.97 and a 200-day moving average price of $775.76. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the firm earned $1.18 EPS. The company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.